Comparison between Pola-R-CHP and R-CHOP regimens in patients newly diagnosed with diffuse large B-cell lymphoma: a...

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• The POLARIX trial established progression-free survival (PFS) benefit for polatuzumab vedotin-based therapy (Pola-R-CHP) over R-CHOP in diffuse large B-cell lymphoma (DLBCL).
• Real-world data for underrepresented populations in POLARIX, such as those with limited-stage disease, low International Prognostic Index (IPI) risk, or advanced age (≥81 years), are limited.

Purpose of the Study:

• To compare the efficacy of Pola-R-CHP versus R-CHOP in a real-world setting, focusing on patient subgroups underrepresented in the POLARIX trial.
• To evaluate the safety and effectiveness of Pola-R-CHP in diverse DLBCL patient populations.

Main Methods:

• A retrospective study comparing newly diagnosed DLBCL patients treated with Pola-R-CHP or R-CHOP.
• Propensity score matching was used to create comparable cohorts (82 pairs).
• Analysis included overall survival (OS) and PFS, stratified by disease stage, IPI risk, and age.

Main Results:

• Pola-R-CHP demonstrated trends toward improved 2-year PFS compared to R-CHOP overall (75.5% vs. 61.4%), in limited-stage disease (96.0% vs. 73.8%), and in low-IPI risk patients (100% vs. 81.2%).
• A significant PFS benefit was observed for Pola-R-CHP in the non-germinal center B-cell (non-GCB) subtype (76.3% vs. 51.0%, p=0.013).
• No significant difference in efficacy was found between the two treatments in patients aged ≥81 years (p=0.43). Age ≥81 was an independent adverse factor for OS in the Pola-R-CHP group (HR 5.44, p=0.044).

Conclusions:

• Real-world findings align with POLARIX, supporting Pola-R-CHP's efficacy in non-GCB DLBCL.
• Pola-R-CHP shows potential benefits in limited-stage or low-IPI risk DLBCL patients, warranting further validation.
• Treatment selection requires careful consideration for patients aged ≥81 years due to potential adverse outcomes.